Tuesday, May 30, 2023


Biotechnology News Magazine


Galapagos and Gilead: Discontinue ISABELA Phase 3 Trials in IPF

February 10, 2021 Galapagos NV and Gilead Sciences decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients...

Biophytis Announces Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.